The ImmunoRevolution that started at Penn is going global.
In August, the European Commission (EC) approved Kymriah®—the pioneering CAR T-cell therapy developed by Dr. Carl June and his team at Penn’s Abramson Cancer Center—for use in the European Union to treat two blood cancers: relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) in pediatric and young adult patients and relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Two international clinical trials, JULIET and ELIANA, affirmed the efficacy and safety of Kymriah in treating patients with ALL and DLBCL, clearing the way for this life-saving innovation to be made available to thousands of patients across the European Union.
“This approval demonstrates the global impact of the therapies we developed in Philadelphia and the far-reaching potential of these therapies to change the way cancer is treated around the world,” says Dr. June, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine in the Perelman School of Medicine and director of the Center for Cellular Immunotherapies in the Abramson Cancer Center.
Kymriah, developed in collaboration with Children’s Hospital of Philadelphia and Novartis, received FDA approval for ALL in August 2017 and DLBCL in May 2018. This exciting news from the European Union is proof positive that Penn is leading the charge in the fight against cancer. Learn more about the transformative impact of this medical breakthrough in the video below.
Donor support is vital to accelerating the discovery of path-breaking cures like Kymriah. You, too, can help propel the ImmunoRevolution. To make a gift, click here or contact Katie Dewees Detzel at email@example.com or (215) 746-1927.